FDA Approves FINGOLIMOD HYDROCHLORIDE — Accord Healthcare Inc.

Accord Healthcare Inc. has received FDA approval for the Abbreviated New Drug Application (ANDA207991) for oral fingolimod hydrochloride, introducing a critical manufacturing competition to the market. This authorization is expected to intensify pricing pressure on branded therapies, potentially driving significant cost savings for patients and payers within the multiple sclerosis sector.